FENC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
19.6M
+9.7%
17.9M
+18.3%
15.1M
+9.7%
13.8M
+10.6%
12.5M
Cost of Revenue
838.0K
+16.2%
721.0K
+26.5%
570.0K
-67.7%
1.8M
+167.3%
660.0K
Gross Profit
18.8M
+9.4%
17.2M
+18.0%
14.5M
+21.0%
12.0M
+1.8%
11.8M
Operating Expenses
14.1M
-8.4%
15.4M
+5.2%
14.7M
+0.6%
14.6M
+21.5%
12.0M
R&D
154.0K
+30.5%
118.0K
+140.8%
49.0K
+145.0%
20.0K
-31.0%
29.0K
SG&A
14.0M
-8.7%
15.3M
+4.7%
14.6M
+0.4%
14.5M
+21.6%
12.0M
Operating Income
4.7M
+167.9%
1.7M
+1559.7%
-119000
+95.3%
-2554000
-1251.3%
-189000
EBITDA
4.7M
+167.9%
1.7M
+1559.7%
-119000
+95.3%
-2554000
-1251.3%
-189000
Net Income
4.6M
+135.2%
2.0M
+881.6%
201.0K
+104.2%
-4787000
-650.3%
-638000
EPS (Basic)
$0.13
+116.7%
$0.06
+500.0%
$0.01
+106.7%
$-0.15
-650.0%
$-0.02
EPS (Diluted)
$0.12
+140.0%
$0.05
+400.0%
$0.01
+106.7%
$-0.15
-650.0%
$-0.02
Shares (Diluted)
38.1M
+4.5%
36.4M
+2.5%
35.5M
+14.0%
31.2M
+11.8%
27.9M
Fennec Pharmaceuticals (FENC) — Financials